DRUG
Fluoxetine 20 MG
fluoxetine
Selective Serotonin Reuptake Inhibitors, Fluoxetine Versus the Standard Oral Desmopressin for Management of Mono-symptomatic Nocturnal Enuresis.
Status
Unknown
Phase
Not applicable
Enrollment
60
Locations
1
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
To determine whether there is a role for the selective serotonin reuptake inhibitors fluoxetine versus desmopressin in the treatment of nocturnal enuresis in children who have not responded to standard nonpharmacological urotherapy, and whether there are side effects involved.
Interventions
Treatment arms and agents.
DRUG
Desmopressin
desmopressin
Timeline
From registration to results.
First posted
Dec 29, 2023
Study start
Dec 1, 2022
Primary completion
Mar 1, 2024
Study completion
Mar 1, 2024
Results posted
Not reported
Registry updated
Dec 29, 2023
Outcomes
What the study measures.
Primary outcomes
The children will be non-responders, partial responders, or full responders to therapy
Time frame · three months
The standardization of terminology of lower urinary tract function in children and adolescents: Update report from the standardization committee of the International Children's Continence Society "ICCS definitions" (i.e., if the reduction of enuresis frequency was below or above 50% or 90%, respectively)
Secondary outcomes
Not reported in the indexed record.
Eligibility
Who can take part.
- Minimum age
- 8 Years
- Maximum age
- 16 Years
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: 1. Age ≥ 7 years 2. Severe enuresis with at least (50%) seven wet nights out of 14 3. Failed treatment 4. The enuresis alarm was either ineffective or considered impractical due to the family circumstances. Exclusion Criteria: 1. Underlying renal, urologic, neurologic, endocrinologic, or cardiac conditions 2. Patients with psychiatric disorders and behavioral disorders including depression, attention-deficit/hyperactivity disorder. 3. Untreated constipation 4. Contraindications to fluoxetine or desmopressin treatment
Study locations
1 registered sites.
Egypt. Showing up to 24 locations stored in the fast local snapshot.
Faculty of medicine, Fayoum University
Al Fayyum, Egypt
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Desmopressin.
NCT IDStudyPhase / statusEnrollmentUpdated
Randomized Controlled Clinical Study on the Prophylactic Intraoperative Use of Desmopressin in Complex Sellar Region Tumors
Zhaoyun Zhang · Craniopharyngiomas · Pituitary Macroadenoma
Phase 4
Enrolling by invitation
152
2026-07
Desmopressin Stimulation Test Performance in ACTH-Dependent Cushing Syndrome
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Cushing Syndrome
Phase 2
Recruiting
140
2026-07
Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial
Hamilton Health Sciences Corporation · Chronic Kidney Diseases · Acute Kidney Injury
Phase 3
Recruiting
100
2026-05
International Multi-center Retrospective Study of Patients With Serum Sodium ≤110 mmol/L to Determine the Relationship Between Osmotic Demyelination Syndrome (ODS) and Rapid Correction of Hyponatremia
Rochester General Hospital · Hyponatremia Symptomatic · Osmotic Demyelination Syndrome
Not applicable
Enrolling by invitation
800
2026-05
DDAVP for Pituitary Adenoma
National Institute of Neurological Disorders and Stroke (NINDS) · Cushing's Disease · Pituitary Adenoma
Not applicable
Recruiting
22
2026-04
Vitamin D Versus Desmopressin Versus Combination Therapy in Children With Primary Monosymptomatic Nocturnal Enuresis and Vitamin D Deficiency
Ain Shams University · Nocturnal Enuresis · Vitamin D Deficiency
Not applicable
Completed
90
2026-03
Ginkgo Biloba vs Desmopressin in Treatment of Children With Monosymptomatic Nocturnal Enuresis
Menoufia University · Nocturnal Enuresis in Children · Desmopressin
Not applicable
Completed
398
2026-01
NOCDURNA PASS Study Using Registries in Denmark, Germany and Sweden
Ferring Pharmaceuticals · Adverse Drug Event
Not applicable
Completed
1,099,551
2025-12
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.